Heatwave and Mental Health (Credit-Freepik)
The heat waves are rising all over the world and causing a lot of damage. While there are issues of dehydration and heat strokes, studies are suggesting that it might also be responsible for declining mental health, the heat among other things is not only affecting the physicality of human beings but is also having adverse mental health.
Emotional distress: The heat can trigger mood swings, making you feel irritable, anxious, depressed, or even aggressive. You may not be able to predict your reaction, you may be good one moment and then any minor inconvenience will make you angry or sad. Heat often triggers that helplessness in people.
Scattered Focus: Concentrating on tasks becomes a struggle when it's hot. Simple things feel overwhelming, and staying focused is a challenge. While you may be in the zone working on completing something, the heat and sweating will disrupt your flow and then you will not be able to focus on anything other than the heat.
Sleepless Nights: High temperatures, especially at night, disrupt your sleep. This lack of rest can leave you feeling tired, and grumpy, and worsen existing mental health issues. All humans require a comfortable temperature to sleep in, if your body is too wound up or heated up, it will not be able to relax and sleep.
Feeling the Pressure: The heat can pile on stress and make you feel overwhelmed. Concerns about the heat itself or its impact on other aspects of your life can contribute to this feeling. You will feel overwhelmed and unable to work on anything else. The heat makes you feel a certain helplessness, as you cannot stop the sun or turn down the heat.
Body Blues: The heat can cause physical symptoms that affect your mental well-being. Headaches, fatigue, dizziness, and nausea can all contribute to anxiety and low mood. When your body is already fatigued, the urge to do anything else disappears. Your body is drained of energy to function at all and will seek rest and sleep.
Behavioural Shifts: The heat can influence your behaviour. You might act impulsively or have difficulty managing anger. It's like the heat turns up your emotional thermostat. When your body and brain are overheating, it is difficult to think straight and you will grasp at straws to release this energy and pressure off of you.
Some other side effects of the heat are.
Credit: iStock/Roche
In a major development for cancer care in India, Swiss pharmaceutical major Roche Pharma has launched Tecentriq SC, the country’s first subcutaneous (under-the-skin) immunotherapy for lung cancer that can be administered in approximately seven minutes.
While conventional intravenous (IV) infusions can take hours, Tecentriq SC can significantly improve the cancer treatment experience by reducing treatment time by nearly 80 per cent.
The seven-minute injectable immunotherapy has the potential to:
“With Tecentriq SC, we are bringing an innovation that meaningfully reduces treatment time while maintaining the established efficacy and safety profile of Tecentriq. We believe such advances can play an important role in enabling more patient-centric and future-ready cancer care delivery in India,” said Roche Pharma India Chief Medical Officer Dr Sivabalan Sivanesan, in a statement.
Tecentriq SC is the first and only PD-(L)1 inhibitor globally with both intravenous (IV) and subcutaneous (SC) formulations across multiple cancers.
First approved by the UK MHRA in 2023 and subsequently by the USFDA in 2024, Tecentriq SC is now approved in more than 85 countries, with over 10,000 patients benefitting globally.
In India, Tecentriq SC is currently approved by the DCGI for adjuvant and metastatic non-small cell lung cancer (NSCLC). NSCLC is the most common form, making up about 80–85% of all cases.
According to Sivanesan, the drug is priced at about "Rs 3.7 lakh per vial".
Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi
Tecentriq SC combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.
The technology uses recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily increases permeability in the subcutaneous space, enabling rapid dispersion and absorption of the medicine into the bloodstream, the company said.
The launch of Tecentriq SC also aligns with the broader shift toward decentralised cancer care in India. Shorter administration formats can free up hospital beds, healthcare staff time, and oncology resources at tertiary care centres, while helping shift care delivery to daycare centres and beyond traditional tertiary hospitals.
“India’s growing cancer burden requires us to rethink how cancer care is delivered. Innovations such as subcutaneous immunotherapy have the potential to simplify treatment administration, reduce pressure on hospital beds and support more decentralised models of care beyond large metro hospitals,” said Dr Amit Rauthan, Consultant and HOD of Medical Oncology at Manipal Hospital.
Global studies have indicated strong patient preference for subcutaneous administration.
According to results from the IMscin002 study presented at the European Lung Cancer Congress (ELCC) 2024:
Studies have also shown that subcutaneous administration is associated with less discomfort, pain, and irritation compared to IV administration.
In the IMscin001 study presented at ESMO 2023:
Credit: AI generated image
Even as Polycystic Ovary Syndrome (PCOS) got rebranded as Polyendocrine Metabolic Ovarian Syndrome (PMOS), it signals a major shift in how doctors understand and treat one of the most common hormonal conditions affecting women, said health experts today.
Speaking to HealthandMe, the experts noted that from the earlier narrowed focus on ovarian cysts, the transition toward PMOS will better capture the condition’s complex metabolic and endocrine nature.
Dr. Isha Kriplani, Consultant – Obstetrics and Gynecology at Paras Health, said the renaming marks “the beginning of a new era in women's gynecological health.”
Also read: PCOS Is Now PMOS: What The Name Change Means For Millions Of Women
The new name aims to explain the condition more accurately and comprehensively.
Polyendocrine means it affects multiple hormones in the body.
Metabolic refers to issues linked to weight, insulin, blood sugar, and heart health.
Ovarian highlights its impact on ovulation and reproductive health.
Syndrome refers to a group of symptoms occurring together.
In simple terms, PMOS is a hormonal and metabolic condition that can affect periods, fertility, skin, mood, weight, and long-term health.
Dr. Isha stated that the term PMOS acknowledges that the disorder is not solely linked to hormonal imbalance or ovarian dysfunction, but also deeply connected to metabolic health. She explained that many women experience symptoms such as weight gain, skin issues, fatigue, insulin resistance, and hormonal disturbances without necessarily showing ovarian cysts on ultrasonography.
“Rebranding Polycystic Ovary Syndrome (PCOS) into Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the beginning of a new era in women's gynecological health. This is because renaming helps us understand that the complex interplay of this disease is not only about imbalanced hormones but also metabolism,” she told HealthandMe.
Dr. Isha added that the shift could help broaden diagnosis and encourage early intervention to prevent long-term complications such as type 2 diabetes and hypertension. She noted that the new terminology also provides women with a more accurate understanding of the syndrome and encourages treatment strategies focused on addressing the root metabolic causes.
Dr. Raina Chawla, Associate Director – Gynecology at Sarvodaya Hospital, told HealthandMe the transition from PCOS to PMOS corrects what she described as one of medicine’s “most persistent misnomers.”
She explained that for years, the term PCOS led many patients to believe the condition was purely ovarian in nature, often resulting in confusion and delays in diagnosis. According to Dr. Raina, the so-called “cysts” seen in PCOS are actually immature follicles that develop as a consequence of the disorder rather than being its primary cause.
Also read: PCOD vs PCOS vs PMOS: Why The Condition’s Name Has Changed Over Time
“The shift from PCOS to Reproductive Metabolic Syndrome (PMOS) is an important move toward correcting one of medicine’s most persistent misnomers,” Dr. Raina said.
She further emphasized that the newer terminology places appropriate attention on insulin resistance and androgen excess, helping doctors and patients approach the disorder as a systemic endocrine and metabolic condition rather than a localized ovarian issue.
Experts believe the change in terminology could also reduce stigma and improve awareness about the wide-ranging symptoms associated with the syndrome, while encouraging a more holistic treatment approach that includes lifestyle modifications, metabolic screening, and long-term preventive care.
Credit: AI generated image
While there have been meaningful improvements in global health over the past decade, in larger terms, the global health progress continues to be ‘fragile and insufficient’, warned the World Health Organization (WHO) in its new report.
The World Health Statistics 2026 report calls for stronger systems to protect progress.
WHO highlighted several major improvements between 2010 and 2024, including:
Despite progress, several global health challenges continue to worsen. These include:
“These data tell a story of both progress and persistent inequality, with many people – especially women, children and those in underserved communities – still denied the basic conditions for a healthy life,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
“Investing in stronger, more equitable health systems, including resilient health data systems is essential to target action, close gaps and ensure accountability,” he added.
Also read: Another Norovirus Outbreak Confirmed Aboard Cruise Ship In France; Over 1,700 People Trapped
The report stressed the urgent need to strengthen universal health coverage (UHC), noting that 1.6 billion people were pushed into poverty due to out-of-pocket healthcare expenses in 2022.
Vaccination coverage also remains below target, contributing to recent measles outbreaks in countries including the US and Bangladesh.
Although maternal mortality has fallen by 40 per cent since 2000, it still remains nearly three times above the 2030 target. Progress in reducing premature deaths from noncommunicable diseases has also slowed since 2015.
Air pollution caused an estimated 6.6 million deaths globally in 2021, while poor water, sanitation, and hygiene contributed to 1.4 million deaths in 2019.
“These trends reflect too many deaths that could have been avoided,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data.
“With rising environmental risks, health emergencies, and a worsening health financing crisis, we must act urgently – strengthening primary health care, investing in prevention, and securing sustainable financing to build resilient health systems and get back on track.”
The WHO report also flagged major gaps in global health data collection.
By the end of 2025, only 18 per cent of countries were reporting mortality data to WHO within one year, while nearly one-third had never submitted cause-of-death data.
Of the estimated 61 million deaths globally in 2023, only about one-third included cause-of-death information, and just one-fifth had properly coded International Classification of Diseases (ICD) data.
"While global health efforts are delivering results, progress is fragile and insufficient," stated the report, while stressing the need for accelerated action, stronger health systems, and improved data to renew progress toward the 2030 health goals.
© 2024 Bennett, Coleman & Company Limited